Remedium is a biotechnology company focused on developing treatments for significant unmet clinical needs. To address these challenges, the company created the Prometheus™ gene therapy platform, a revolutionary system that enables the safe, effective, and long-lasting delivery of therapeutic genes. This platform also uniquely allows for simple post-treatment dose adjustment. Prometheus™ has the potential to replace a wide range of frequently administered protein treatments with a single, adjustable-dose gene therapy injection, drastically reducing treatment costs. Remedium's pipeline includes several disease-modifying treatments showing promising efficacy in endocrinology, immunology, neurology, and musculoskeletal diseases. The company operates out of Lilly Gateway Labs in Boston, which is part of the Lilly Catalyze360™ model designed to support early-stage biotech startups.